{"created":"2023-06-19T12:16:29.040768+00:00","id":1153,"links":{},"metadata":{"_buckets":{"deposit":"88cae401-86ae-421a-bc69-4775c1c0ab86"},"_deposit":{"created_by":3,"id":"1153","owners":[3],"pid":{"revision_id":0,"type":"depid","value":"1153"},"status":"published"},"_oai":{"id":"oai:hachinohe-hachitan.repo.nii.ac.jp:00001153","sets":["248:359"]},"author_link":["409"],"item_10002_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2017-03-31","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"54","bibliographicPageEnd":"25","bibliographicPageStart":"7","bibliographic_titles":[{"bibliographic_title":"八戸学院大学紀要"}]}]},"item_10002_description_6":{"attribute_name":"内容記述","attribute_value_mlt":[{"subitem_description":"分子標的薬は、特有あるいは過剰に発現している特定の標的（分子）の機能を抑える作用を有し、1980年代からモノクローナル抗体の投与が悪性腫瘍（がん）に対して行われ、1990年代には低分子化合物が登場した。血液疾患、主に白血病や多発性骨髄腫などの造血器悪性腫瘍では、イマチニブやリツキサンなどの分子標的薬により、予後の改善、さらには治癒が得られるようになった。近年、新しい分子標的薬が開発中で、臨床応用に向けて研究が進んでおり、有用なデータが集積しつつある。","subitem_description_type":"Other"}]},"item_10002_select_24":{"attribute_name":"論文種別","attribute_value_mlt":[{"subitem_select_item":"総説"}]},"item_10002_select_25":{"attribute_name":"学部学科","attribute_value_mlt":[{"subitem_select_item":"健康医療学部看護学科"}]},"item_10002_select_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_select_item":"八戸学院大学"}]},"item_10002_select_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_select_item":"2187-8102"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"高橋, 正知"}],"nameIdentifiers":[{"nameIdentifier":"409","nameIdentifierScheme":"WEKO"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2017-03-31"}],"displaytype":"simple","filename":"八戸学院大学紀要 第54号_0002.pdf","filesize":[{"value":"1.3 MB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"PDF(本文)","url":"https://hachinohe-hachitan.repo.nii.ac.jp/record/1153/files/八戸学院大学紀要 第54号_0002.pdf"},"version_id":"bd211617-88a1-425e-ab64-7bcad3786236"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"血液疾患","subitem_subject_scheme":"Other"},{"subitem_subject":"分子標的治療","subitem_subject_scheme":"Other"},{"subitem_subject":"Hematological disease","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Targeted therapy","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"departmental bulletin paper","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"血液疾患の分子標的治療","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"血液疾患の分子標的治療"},{"subitem_title":"Molecular targeted therapy in hematological diseases","subitem_title_language":"en"}]},"item_type_id":"10002","owner":"3","path":["359"],"pubdate":{"attribute_name":"公開日","attribute_value":"2017-03-31"},"publish_date":"2017-03-31","publish_status":"0","recid":"1153","relation_version_is_last":true,"title":["血液疾患の分子標的治療"],"weko_creator_id":"3","weko_shared_id":-1},"updated":"2023-06-19T12:24:49.371114+00:00"}